[Corrections] Correction to Lancet Infect Dis 2023; published online Aug 21. https://doi.org/10.1016/S1473-3099(23)00393-6

Di |2023-09-30T00:30:01+02:00Settembre 30th, 2023|Categorie: Coronavirus Lancet|

Maranda B, Labbé SM, Lurquin M, et al. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2023; published online Aug 21. https://doi.o...

[Corrections] Correction to Lancet Infect Dis 2023; published online Aug 21. https://doi.org/10.1016/S1473-3099(23)00393-6

Di |2023-09-30T00:30:01+02:00Settembre 30th, 2023|Categorie: Coronavirus Lancet|

Maranda B, Labbé SM, Lurquin M, et al. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2023; published online Aug 21. https://doi.o...

[Articles] Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Di |2023-09-29T00:30:01+02:00Settembre 29th, 2023|Categorie: Coronavirus Lancet|

Both molnupiravir and ritonavir-boosted nirmatrelvir accelerate oropharyngeal SARS-CoV-2 viral clearance in patients with COVID-19, but the antiviral effect of ritonavir-boosted nirmatrelvir was substantially greater. Measurement of oropharyngeal viral...

[Articles] Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Di |2023-09-29T00:30:01+02:00Settembre 29th, 2023|Categorie: Coronavirus Lancet|

Both molnupiravir and ritonavir-boosted nirmatrelvir accelerate oropharyngeal SARS-CoV-2 viral clearance in patients with COVID-19, but the antiviral effect of ritonavir-boosted nirmatrelvir was substantially greater. Measurement of oropharyngeal viral...

[Comment] The Dengue-in-Dhaka Initiative: results from a phase 2 trial evaluating the TV005 tetravalent dengue vaccine in Bangladesh

Di |2023-09-28T00:30:03+02:00Settembre 28th, 2023|Categorie: Coronavirus Lancet|

Dengue poses an ongoing public health threat in most tropical and subtropical regions, and is poised to increase further in incidence and geographic distribution.1 The Laboratory of Infectious Diseases at the National Institutes of Health (NIH)–Nationa...

[Comment] The Dengue-in-Dhaka Initiative: results from a phase 2 trial evaluating the TV005 tetravalent dengue vaccine in Bangladesh

Di |2023-09-28T00:30:03+02:00Settembre 28th, 2023|Categorie: Coronavirus Lancet|

Dengue poses an ongoing public health threat in most tropical and subtropical regions, and is poised to increase further in incidence and geographic distribution.1 The Laboratory of Infectious Diseases at the National Institutes of Health (NIH)–Nationa...